• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

    9/9/24 5:42:44 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TBPH alert in real time by email
    SC 13G/A 1 ef20035682_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934 (Amendment No.  09 )*
     
    Theravance Biopharma, Inc

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    G8807B106

    (CUSIP Number)
     
    August 31, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☑  Rule 13d-1(b)
     
    ☐ Rule 13d-1(c)
     
    ☐ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No
    G8807B106
     
    1
    NAMES OF REPORTING PERSONS
     
     
    The Baupost Group, L.L.C.
    04-3402144
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☑
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    State of Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     

    FOOTNOTES


    CUSIP No
    G8807B106
     
    1
    NAMES OF REPORTING PERSONS
     
     
    Baupost Group GP, L.L.C.
    82-3254604
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☑
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    State of Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC
     
     
     
     

    FOOTNOTES


    CUSIP No
    G8807B106
     
    1
    NAMES OF REPORTING PERSONS
     
     
    Seth A. Klarman
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☑
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    The United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC
     
     
     
     
     
    FOOTNOTES


    Item 1.
     

    (a)
    Name of Issuer


    Theravance Biopharma, Inc.


    (b)
    Address of Issuer’s Principal Executive Offices


    901 Gateway Boulevard


    South San Francisco, CA 94080

    Item 2.
     

    (a)
    Name of Person Filing
      (1)
    The Baupost Group, L.L.C.

    (2)
    Baupost Group GP, L.L.C.

    (3)
    Seth A. Klarman
     

    (b)
    Address of Principal Business Office or, if none, Residence
      (1)
    The Baupost Group, L.L.C.
    10 St. James Avenue, Suite 1700
    Boston, Massachusetts 02116

    (2)
    Baupost Group GP, L.L.C.
    10 St. James Avenue, Suite 1700
    Boston, Massachusetts 02116

    (3)
    Seth A. Klarman
    10 St. James Avenue, Suite 1700
    Boston, Massachusetts 02116
     

    (c)
    Citizenship

    (1)
    The Baupost Group, L.L.C.: State of Delaware

    (2)
    Baupost Group GP, L.L.C.: State of Delaware

    (3)
    Seth A. Klarman: The United States of America
     

    (d)
    Title of Class of Securities


    Common Stock


    (e)
    CUSIP Number


    G8807B106

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)
    ☑
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    ☑
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    ☐
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
    (k)
    ☐
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
      (a)
    Amount beneficially owned:
      (1)
    The Baupost Group, L.L.C.: 0

    (2)
    Baupost Group GP, L.L.C.: 0

    (3)
    Seth A. Klarman: 0
     

    (b)
    Percent of class:

    (1)
    The Baupost Group, L.L.C.: 0%

    (2)
    Baupost Group GP, L.L.C.: 0%

    (3)
    Seth A. Klarman: 0%
     

    (c)
    Number of shares as to which the person has:
     
      (i)
    Sole power to vote or to direct the vote:

    (1)
    The Baupost Group, L.L.C.: 0

    (2)
    Baupost Group GP, L.L.C.: 0

    (3)
    Seth A. Klarman: 0
     

    (ii)
    Shared power to vote or to direct the vote:

    (1)
    The Baupost Group, L.L.C.: 0

    (2)
    Baupost Group GP, L.L.C.: 0

    (3)
    Seth A. Klarman: 0
     


    (iii)
    Sole power to dispose or to direct the disposition of:
     

    (1)
    The Baupost Group, L.L.C.: 0

    (2)
    Baupost Group GP, L.L.C.: 0

    (3)
    Seth A. Klarman: 0
     

    (iv)
    Shared power to dispose or to direct the disposition of:

    (1)
    The Baupost Group, L.L.C.: 0

    (2)
    Baupost Group GP, L.L.C.: 0

    (3)
    Seth A. Klarman: 0
     
    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☑

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Securities reported on this statement on Schedule 13G as being beneficially owned by The Baupost Group, L.L.C. were purchased on behalf of various private investment limited partnerships.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    See footnote.

    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A

    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    SIGNATURE
     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Baupost Group, L.L.C.
       
    Date: September 9, 2024
    By: 
     /s/ Seth A. Klarman
     
    Name: Seth A. Klarman
     
    Title: Chief Executive Officer
       
     
    Baupost Group GP, L.L.C.
       
    Date: September 9, 2024
    By: 
     /s/ Seth A. Klarman
     
     
     Name: Seth A. Klarman
     
    Title: Managing Member
       
     
    Seth A. Klarman
       
    Date: September 9, 2024
    By: 
     /s/ Seth A. Klarman
     
    Name: Seth A. Klarman

    Footnotes: Item 3, Item 4 and Item 7
     
    This statement on Schedule 13G is being jointly filed by The Baupost Group, L.L.C. ("Baupost"), Baupost Group GP, L.L.C. (“BG GP”) and Seth A. Klarman. Baupost is a registered investment adviser and acts as an investment adviser and general partner to various private investment limited partnerships. Securities reported on this statement on Schedule 13G as being beneficially owned by Baupost were purchased on behalf of certain of such partnerships. BG GP, as the Manager of Baupost, and Seth A. Klarman, as the Managing Member of BG GP and a controlling person of Baupost, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended, of the securities beneficially owned by Baupost.
     
    Pursuant to Rule 13d-4, Seth A. Klarman and BG GP declare that the filing of this statement on Schedule 13G shall not be deemed an admission by either or both of them that they are, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any securities covered by this statement on Schedule 13G.
     
    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     


    Get the next $TBPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TBPH

    DatePrice TargetRatingAnalyst
    8/6/2024$15.00 → $10.00Outperform → Market Perform
    Leerink Partners
    4/12/2024$21.00Buy
    BTIG Research
    1/8/2024Outperform → In-line
    Evercore ISI
    5/23/2022$12.00Outperform
    SVB Leerink
    3/2/2022$10.00 → $11.00Underweight
    Morgan Stanley
    2/24/2022$8.00 → $12.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $12.00Underweight → Neutral
    JP Morgan
    9/16/2021$14.00 → $10.00Underweight
    Morgan Stanley
    More analyst ratings

    $TBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Theravance Biopharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously

      8/6/24 8:00:45 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Theravance Biopharma with a new price target

      BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00

      4/12/24 7:40:50 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma downgraded by Evercore ISI

      Evercore ISI downgraded Theravance Biopharma from Outperform to In-line

      1/8/24 8:38:16 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

      Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billionFirst outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning exces

      6/2/25 6:00:00 AM ET
      $GSK
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma to Participate in an Upcoming Investor Conference

      DUBLIN, May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference. A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma

      5/13/25 6:00:00 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

      DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts. A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (NCT03829657), an international phase 3, pl

      5/9/25 12:00:00 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      8/9/24 6:02:35 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      5/3/24 4:19:22 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,600 units of Ordinary Shares and received a gift of 9,600 units of Ordinary Shares, decreasing direct ownership by 0.54% to 1,753,180 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      6/17/25 6:16:33 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $264,000 worth of Ordinary Shares (24,000 units at $11.00), decreasing direct ownership by 7% to 336,918 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      6/4/25 6:04:21 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,364 units of Ordinary Shares, decreasing direct ownership by 0.86% to 1,762,780 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      5/22/25 6:44:56 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    SEC Filings

    See more
    • Theravance Biopharma Inc. filed SEC Form 8-K: Other Events

      8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

      6/6/25 6:03:07 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

      6/2/25 6:02:21 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

      5/20/25 5:00:27 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care